HEOR and the Global Value Dossier: Building Device Evidence That Wins Reimbursement

A guide to HEOR and Global Value Dossier strategy for medical devices. Dissects device-specific economic modeling and payer evidence requirements.

Securing regulatory clearance or CE marking is no longer the final hurdle for medical device commercialization. In today’s value-based healthcare environment, the true gatekeeper to patient access is the payer. Whether it is a private insurance company in the United States, a national health system in the United Kingdom, or a regional health technology assessment (HTA) body in continental Europe, public and private payers demand robust evidence that a new medical technology not only works in clinical trials but also delivers tangible economic value in real-world clinical practice.

To bridge this gap between regulatory approval and commercial reimbursement, medical device manufacturers must leverage Health Economics and Outcomes Research (HEOR) and package their evidence into a comprehensive Global Value Dossier (GVD). This article delivers a strategic playbook for market-access and HEOR leads, outlining payer evidence standards, the unique challenges of device HEOR compared to pharmaceuticals, the structure of a high-impact GVD, and the mechanics of budget-impact and cost-effectiveness modeling. For the coding, coverage, and payment mechanics this evidence ultimately feeds into, see our complete medical device reimbursement guide.

Scenario Question: We are launching a Class III device across the US and EU. What HEOR evidence and Global Value Dossier will payers and HTA bodies expect, and how is it different from drug evidence?

Direct Answer: Payers and HTA bodies require evidence that a device improves patient outcomes and offers acceptable cost-effectiveness, typically framed as cost per QALY plus a budget-impact model from the specific payer perspective. Devices are harder to evidence than drugs because of rapid iterative improvement, learning-curve effects, user-dependent outcomes, and limited randomized data, so HEOR planning should start 2 to 5 years before launch. A Global Value Dossier standardizes the product value story and its supporting evidence so the same core (clinical, economic, and patient-reported evidence plus a budget-impact and cost-effectiveness model) can be localized across markets rather than rebuilt for each one.

1. What HEOR Evidence Do Payers and HTA Bodies Require for a Medical Device?

Payers and HTA bodies have different mandates than regulators like the FDA or Notified Bodies. Regulators assess safety and performance—whether the device performs as intended without causing unacceptable harm. Payers assess clinical and economic value—whether the device improves outcomes compared to the current established treatment standard and whether the additional clinical benefit justifies the financial cost.

A peer-reviewed scoping review of high-risk device reimbursement pathways across the EU/EEA and UK (Alshaikh et al. 2025) documents how decision-makers weigh comparative clinical, economic, and safety evidence in coverage decisions. In practice, the evidence payers and HTA bodies evaluate clusters into three primary pillars:

Clinical Efficacy and Comparative Effectiveness: Payers want to see how the device performs against the active comparator representing the current established treatment standard in their specific jurisdiction. A placebo-controlled trial is often insufficient; if a payer currently covers a drug therapy or an older surgical procedure, they expect direct or indirect head-to-head evidence showing superior clinical outcomes (e.g., lower recurrence rates, fewer complications, or faster recovery times).
Economic Value and Health Economics: Manufacturers must demonstrate that the clinical benefits translate into economic savings or acceptable spending thresholds. This is quantified through cost-effectiveness models (measuring the cost to achieve a unit of health benefit) and budget-impact models (measuring the net financial impact on the payer's budget over a 3-to-5-year horizon).
Humanistic Value and Patient-Reported Outcomes (PROs): Payers increasingly prioritize patient-centric metrics. This includes quality-of-life improvements, pain reduction scales, and functional independence measures. These PROs are often captured using standardized questionnaires (e.g., EQ-5D, SF-36) and are critical for calculating Quality-Adjusted Life Years (QALYs).

When preparing HEOR evidence for HTA reviews, manufacturers must understand that these three pillars are interdependent. A device with excellent clinical data but no economic model will struggle to secure coverage, while an economic model built on weak clinical assumptions will be rejected by HTA assessors.

2. How Do Device HEOR Challenges Change the Evidence Plan?

Many HEOR methodologies were originally developed for the pharmaceutical industry, where molecules remain chemically static from clinical trials through their entire commercial lifecycle. Applying these drug-centric HEOR frameworks to medical devices is a common failure mode. Health economics reviewers consistently flag four device-specific challenges that drug frameworks miss: rapid innovation and short lifecycles, user-dependent outcomes, surgical learning-curve effects, and limited high-quality randomized data (MTRC; ISPOR/EVERSANA device evidence panel). Devices possess unique engineering and operational characteristics that require tailored research designs.

Rapid Iteration and Short Lifecycles

Unlike a small molecule drug that may take 12 years to develop and remain unchanged for decades, medical devices are subject to rapid, iterative engineering cycles. A physical device is often updated every 18 to 24 months to improve usability, address minor safety issues, or lower manufacturing costs.

This rapid lifecycle presents a major HEOR challenge. By the time a manufacturer conducts a multi-year randomized clinical trial and compiles the economic evidence for a specific device version, that version may already be obsolete. Payers must be convinced that the clinical and economic data generated on version 1.0 is generalizable to version 2.0 or 3.0. HEOR teams must establish "bridging" frameworks, using bench testing, usability studies, and early real-world registry data to demonstrate that minor design modifications do not degrade—and may improve—the established value case.

The Surgical Learning Curve

A drug's clinical effect is largely determined by its chemical structure and dosage. A medical device's clinical effect is heavily dependent on the skill, experience, and training of the clinician implanting or operating it.

This learning curve creates a variable evidence baseline. Early clinical trials conducted by world-class, high-volume key opinion leaders (KOLs) often show superior outcomes compared to those achieved by general surgeons in community hospitals during early commercial launch. HEOR models must account for this learning curve. If clinical outcomes improve after a surgeon performs 10, 20, or 50 procedures, the cost-effectiveness model must reflect this transition, incorporating the higher initial complication rates and the subsequent stabilization of outcomes in real-world use.

User-Dependent and Non-Blinded Outcomes

Blinding is the gold standard of drug trials to prevent bias. For medical devices, blinding is often physically impossible or ethically unjustifiable. A surgeon knows whether they are implanting a novel artificial heart valve or performing a traditional surgical repair, and the patient often knows what procedure they underwent.

Furthermore, outcomes are highly dependent on the hospital infrastructure and post-operative care. HEOR teams must compensate for this lack of blinding and high variability by incorporating robust secondary endpoints, utilizing independent blinded assessors for clinical outcomes, and gathering extensive real-world evidence in the value dossier to demonstrate that the value case holds across diverse hospital settings.

Table 1: HEOR Evidence Differences: Medical Devices vs. Pharmaceuticals

Characteristic	Pharmaceutical Drugs	Medical Devices	HEOR Strategy Implication
Product Stability	Static chemical structure	Iterative engineering cycles	Must establish bridging evidence for device upgrades.
User Dependence	Low (uniform administration)	High (surgical skill & learning curve)	Model must incorporate learning curve variables.
Blinding Feasibility	High (double-blind placebo)	Low (sham controls rare/difficult)	Rely on blinded objective assessors and real-world registries.
Evidence Lifecycle	Heavy pre-market RCT data	Incremental pre-market + heavy post-market RWE	Use post-market registries to refine economic models.
Pricing Model	Cost per dose / package	Capital equipment + consumable kits	Model capital depreciation and hospital operational costs.

3. What Goes into a Device Global Value Dossier and How Is It Structured?

A Global Value Dossier (GVD) is a comprehensive, centralized document repository that houses the entire clinical, humanistic, and economic value story of a medical technology. It is developed by the global market-access team and serves as the single source of truth for the product.

The primary objective of a GVD is to standardize the product’s value proposition while providing local affiliates (e.g., country managers, regional access leads) with the technical tools needed to localize the submission for their specific national payers. Rebuilding a reimbursement submission from scratch in every country is highly inefficient and leads to inconsistent messaging; localizing a standardized global dossier ensures speed and strategic alignment.

A standard medical device GVD is structured into five core sections:

Section 1: Clinical Value Story and Unmet Need

This section establishes the therapeutic context. It details the epidemiology and burden of the disease under study, outlines the clinical limitations and financial costs of current treatments, and introduces the new device as a solution to an unaddressed clinical gap. Rather than presenting pure clinical facts, this section frames the disease through the lens of the payer, highlighting the high cost of treatment failures, repeat hospitalizations, and long-term disability under the status quo.

Section 2: Clinical Evidence and Product Safety

This section compiles all available clinical evidence supporting the device. It includes peer-reviewed data from primary clinical trials, post-market registries, systematic literature reviews, and meta-analyses. For devices, this section must place special emphasis on:

The device pathway: Detail whether the clinical data supported an FDA PMA or was compiled for CE marking under the EU MDR.
Safety profile: Provide detailed complication rates, device malfunction data, and long-term implant survival rates.
GCP and Standards compliance: Cite compliance with GCP guidelines and ISO 14155 to establish data integrity.

Section 3: Humanistic and Patient-Reported Value

This section focuses on the patient experience. It details how the device improves quality of life, functional capacity, and patient satisfaction. By compiling PRO data, manufacturers can argue that even if a device does not extend life expectancy, it significantly reduces pain, accelerates return to work, or eliminates the need for daily medication, creating massive humanistic value that indirect HTA models (like QALY calculations) capture.

Section 4: Economic Value and Health Economic Models

This is the quantitative core of the GVD. It contains the technical documentation, user guides, and default inputs for the cost-effectiveness and budget-impact models. For medical devices, this section must separate capital costs (e.g., the upfront price of a surgical robot or diagnostic console) from consumable costs (e.g., single-use disposable kits) and maintenance contracts, allowing payers to evaluate the total cost of ownership.

Section 5: Localization Toolkit

The localization toolkit is the operational bridge of the GVD. It provides guidance on how to adapt the global value messages to fit local regulatory and pricing frameworks. For example, it explains how a local affiliate should adjust the dossier to align with the US Medicare coverage pathways or translate the economic arguments to satisfy the specific HTA requirements of national bodies like NICE in the UK or the G-BA in Germany.

4. How Do Budget-Impact and Cost-Effectiveness Models Fit the Dossier and the Payer Perspective?

The economic models in Section 4 of the GVD are the tools that translate clinical data into currency. Payers evaluate these models to decide whether to cover a device and, if so, at what price. HEOR teams must understand the distinct purposes and mathematical structures of these two model types.

Cost-Effectiveness Models: The Long-Term Value Case

Cost-effectiveness models (often structured as cost-utility analyses) evaluate the long-term value of a technology over a patient's lifetime or a multi-year horizon. The standard output of a cost-effectiveness model is the Incremental Cost-Effectiveness Ratio (ICER), which measures the additional cost required to gain one additional unit of health benefit:

ICER = (Cost of new device − Cost of standard care) ÷ (Health effect of new device − Health effect of standard care)

The health benefit is typically measured in Quality-Adjusted Life Years (QALYs), which combine survival duration with quality-of-life weights (from 0 for death to 1 for perfect health). HTA bodies evaluate whether the calculated ICER falls below a national "willingness-to-pay" threshold. For example, NICE in the UK applied a £20,000-to-£30,000-per-QALY reference range for over two decades; following a December 2025 UK government announcement, NICE applies raised thresholds of £25,000 to £35,000 per QALY to evaluations from April 2026. US benchmarks often range from $50,000 to $150,000 per QALY.

Cost-effectiveness models are critical for establishing the value of innovative, curative, or preventive technologies that carry a high upfront cost but generate long-term savings by preventing future hospitalizations or major clinical events.

Budget Impact Models: The Short-Term Cash Flow Case

While cost-effectiveness models focus on long-term value, budget-impact models (BIMs) focus on short-term affordability. A payer may agree that a device is highly cost-effective over a 20-year lifetime, but they must know how much cash will flow out of their budget over the next 12 to 36 months if they approve coverage today.

Under the ISPOR Good Practice Principles for Budget Impact Analysis (Mauskopf et al. 2007, updated by the ISPOR Budget Impact Analysis Good Practice II Task Force in 2014)—the methodological standard cited in over a thousand health economics analyses—a budget impact model must take the perspective of the specific healthcare decision-maker. The model calculates the net cost change by comparing two scenarios:

The Reference Scenario: The total cost of treating the eligible patient population under the current mix of health technologies (without the new device).
The New Device Scenario: The total cost of treating the same population once the new device is introduced and captures a predicted share of the market.

A BIA must incorporate local population sizing, taking the total covered lives of a payer and narrowing it down to the specific sub-population eligible for the device. The model must capture all relevant direct costs:

Acquisition costs: The invoice price of the device and associated consumables.
Procedure costs: Surgeon fees, operating room time, anesthesia, and imaging.
Complication costs: The financial cost of treating short-term adverse events.
Resource offsets: Reductions in hospital length of stay, intensive care unit (ICU) days, or post-discharge home care.

By showing that a device reduces hospital length of stay by 1.5 days or prevents 5% of readmissions, a budget impact model can demonstrate that the new technology pays for itself within the payer’s fiscal year, converting a purchasing hurdle into a business justification.

5. How Do You Sequence Evidence Generation Across Regulatory and Market-Access Timelines?

A common commercialization failure is treating HEOR as a post-launch activity. If a manufacturer waits until FDA clearance or CE marking to begin developing their economic models and GVD, they will face a "reimbursement valley of death"—a 12-to-24-month period where the product is legally cleared for sale but cannot capture market share because payers have not established coverage or codes.

To prevent this delay, evidence generation must be strategically sequenced across the product development lifecycle:

Table 2: Medical Device HEOR and Access Evidence Sequencing

Lifecycle Stage	Timing	Core HEOR & Access Activities	Expected Output / Deliverable
R&D / Early Feasibility	2 to 5 years pre-launch	Map reimbursement landscape, review competitor HTA files, define target price.	Target Product Profile (TPP) with reimbursement specs.
Premarket / Pivotal	1 to 2 years pre-launch	Embed economic and quality-of-life endpoints in pivotal trials, draft budget impact model.	Preliminary budget impact tool and patient-reported outcomes (PRO) strategy.
Regulatory / Pre-Launch	6 to 12 months pre-launch	Compile GVD, build cost-effectiveness and budget-impact models, obtain external peer-review.	Final Global Value Dossier (GVD) and economic models.
Launch / Submission	Launch window	Localize GVD text, adapt economic model parameters (labor, codes, demographics).	Country-specific reimbursement and HTA submission packages.
Post-Market	1 to 2 years post-launch	Gather real-world registry evidence, analyze hospital billing records for procedural offsets.	Updated economic models based on real-world cost-effectiveness.

Strategic Alignment Phases

Phase 1: Strategic Planning (2 to 5 Years Before Launch): During early R&D and feasibility design, the HEOR team must map the reimbursement landscape in target markets. They identify the relevant HTA bodies, review existing coverage decisions for competitor devices, and define the target price. This information is used to shape the clinical trial design, ensuring that the trial collects the clinical and economic endpoints (e.g., quality of life surveys, hospital resource utilization) needed for subsequent submissions.
Phase 2: Evidence Collection (1 to 2 Years Before Launch): As the pivotal trial progresses, the draft budget impact and cost-effectiveness models are developed. These models use preliminary clinical trial data combined with literature benchmarks to test the price sensitivity and identify the key drivers of economic value.
Phase 3: Dossier Compilation (6 to 12 Months Before Launch): The GVD is written, integrating the final clinical trial results, safety databases, and economic models. This document is peer-reviewed by external clinical and economic experts to ensure its scientific validity.
Phase 4: Localization and Submission (Launch Window): The GVD is handed over to the local affiliates. They adjust the model inputs (e.g., local labor rates, diagnostic codes, and patient demographics) to match their national requirements and submit the packages to local HTA bodies and payers. In the US, manufacturers holding a Breakthrough Device designation should also evaluate the expedited CMS coverage pathways for breakthrough devices during this window.
Phase 5: Post-Market Refinement (1 to 2 Years Post-Launch): The global team gathers real-world evidence (registries, hospital billing databases) to verify the assumptions used in the pre-launch models. If the real-world data shows higher procedural efficiency or lower complication rates than the trial data, the economic models are updated to support price increases or premium positioning.

By integrating HEOR planning early in the product lifecycle, manufacturers can align their clinical trial execution with payer expectations, ensuring that regulatory clearance and reimbursement coverage occur in close succession.

FAQ Section

Do medical devices need cost-effectiveness and QALY evidence like drugs?

It depends on the country and the clinical pathway. In countries with formal HTA systems (such as the UK, Canada, Australia, and parts of Europe), cost-effectiveness evidence expressed as cost-per-QALY is often mandatory for national medical device coverage. In the United States, private payers and Medicare focus heavily on clinical utility and short-term budget impact, though cost-effectiveness data is increasingly used to support premium pricing and value-based purchasing agreements in hospital systems.

What is the difference between a budget impact model and a cost-effectiveness model for devices?

A cost-effectiveness model evaluates the long-term clinical and economic value of a device over a patient's lifetime, measuring whether the clinical benefit (e.g., QALYs gained) justifies the additional cost. A budget impact model evaluates the short-term financial affordability of the technology for a specific payer over a 1-to-3-year horizon, calculating the net cash flow impact of introducing the new device into the payer's covered population.

How early should HEOR planning start before device launch?

HEOR strategic planning should start 2 to 5 years before launch, ideally during the design of the premarket clinical trial protocol. This early start is necessary to ensure that the clinical trial collects the specific economic and quality-of-life endpoints required by HTA bodies, preventing the need to conduct expensive and time-consuming secondary studies post-clearance.

How does a Global Value Dossier differ from a single-country submission?

A Global Value Dossier (GVD) is a standardized, comprehensive master document that houses all the clinical, humanistic, and economic evidence for a product. It serves as a central resource for the company. A single-country submission is a localized application tailored to the specific formatting, language, coding, and economic requirements of a single national payer or HTA body, built using the data and value stories extracted from the GVD.

References

ISPOR. Principles of Good Practice for Budget Impact Analysis (Mauskopf et al. 2007). Value in Health, 10(5), 336-347. ispor.org/heor-resources/good-practices/article/principles-of-good-practice-for-budget-impact-analysis; PubMed 17888098. Updated by: Sullivan, S. D., et al. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1), 5-14. PubMed 24438712.
Alshaikh, R. A., et al. (2025). Mapping current decision-making pathways and reimbursement processes for high-risk medical devices in EU/EEA member states and the UK: a scoping review. International Journal of Technology Assessment in Health Care, 41(1), e78. PMC12592967.
Med Tech Reimbursement Consulting (MTRC). Challenges of Health Economic Evaluations of Medical Devices (Report #10). mtrconsult.com/challenges-health-economic-evaluations-medical-devices.
EVERSANA / Association of Healthcare Value Analysis Professionals (AHVAP). Evidence Standards for Medical Device Adoption by US Hospitals (ISPOR panel). eversana.com.
ISPOR. Assessing the Value of Medical Devices — Choosing the Best Path. Value & Outcomes Spotlight, May/June 2017. ispor.org/publications/value-outcomes-spotlight.
U.S. Food and Drug Administration. Regulations: Good Clinical Practice and Clinical Trials. fda.gov.
NICE. Changes to NICE's cost-effectiveness thresholds confirmed (1 December 2025). nice.org.uk.